Variable | Â | CLD+ | CLD- | P |
---|---|---|---|---|
Site | Zimbabwe | 72% (241/336) | 74% (55/74) | 0.770 |
Sex | Female | 49% (166/336) | 62% (46/74) | 0.054 |
Age | Median (IQR) | 15 (13–18) | 16 (12–18) | 0.939 |
Anthropometric | ||||
 BMI-for-age  z -score2 | Median (IQR) | −1.114 (− 1.85, −0.28) | − 0.32 (− 0.83, − 0.58) | < 0.001 |
 Height-for-age z-score a | <− 2 (Stunted) | 50% (168/336) | 30% (22/74) | 0.002 |
 Weight-for-age z-score a | <−2 (Underweight) | 52% (176/336) | 19% (14/74) | < 0.001 |
Current drug use | ||||
 Cotrimoxazole (CTX) |  | 91% (304/334) | 86% (60/70) | 0.188 |
 Antiretroviral regimen | λNNRTI-based regimen -1st line | 74% (247/335) | 89% (65/73) | 0.006 |
 | §PI-based regimen-2nd line | 26% (88/335) | 11% (8/73) | |
HIV clinical parameters | ||||
 CD4 count categories | > 500 cells/mm | 62% (208/336) | 67% (49/73) | 0.770 |
 | 200–500 cells/mm | 28% (94/336) | 25% (18/73) | |
 | < 200 cells/mm | 10% (34/336) | 8% (6/73) | |
 Viral load (VL) suppression | VL < 1000 copies/mL | 56% (187/336) | 66% (49/74) | 0.119 |
 Age at ART initiation | Median (IQR) | 8 (6–12) | 9 (5–11) | 0.667 |
 Years spent on ART | Median (IQR) | 6 (4–9) | 7 (4–9) | 0.571 |
Respiratory status | ||||
 Previously treated for TB, % (N) |  | 29% (97/335) | 12% (9/73) | 0.003 |
 FEV1 z-score | Median (IQR) | −1.96 (−2.46, −1.47) | 0.52 (0.23, 0.79) | < 0.001 |
 Admitted for chest problems in last 12 months |  | 2% (6/336) | 1% (1/74) | 1 |
 Asthma |  | 3% (11/336) | 0% (0/74) | 0.227 |
 MRC dyspnoea Score | 1 | 55% (185/336) | 78% (59/73) | 0.001 |
 | 2 | 35% (120/336) | 16% (12/73) | |
 | 3 | 6% (19/336) | 3% (2/73) | |
 | 4 | 3% (10/336) | 0% (0/73) | |
 | 5 | 1% (2/336) | 0% (0/73) |